• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Biohaven Pharmaceutical Holding Company Ltd. (Amendment)

    2/11/22 11:19:52 AM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BHVN alert in real time by email
    SC 13G/A 1 SEC13G_Filing.htm SEC SCHEDULE 13G

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 3 )*

                

    Biohaven Pharmaceutical Holding Co. Ltd.


    (Name of Issuer)

    Common Stock


    (Title of Class of Securities)

    G11196105


    (CUSIP Number)

    December 31, 2021


    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [X] Rule 13d-1(b)
    [ ] Rule 13d-1(c)
    [ ] Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes.)


    CUSIP No. G11196105

    1. NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

    Capital International Investors
    95-1411037
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a) [ ]
    (b) [ ]
    3. SEC USE ONLY
    4. CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

    5. SOLE VOTING POWER 5,102,981
    6. SHARED VOTING POWER 0
    7. SOLE DISPOSITIVE POWER 5,104,501
    8. SHARED DISPOSITIVE POWER 0
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    5,104,501 Beneficial ownership disclaimed pursuant to Rule 13d-4
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    [ ]
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    7.8%
    12. TYPE OF REPORTING PERSON

    IA

    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    


    Item 1.
    (a) Name of Issuer
    Biohaven Pharmaceutical Holding Co. Ltd.
    (b) Address of Issuer's Principal Executive Offices
    215 Church Street, New Haven, CT 06510
    Item 2.
    (a) Name of Person Filing
    Capital International Investors
    (b) Address of Principal Business Office or, if None, Residence
    333 South Hope Street, 55th Fl, Los Angeles, CA 90071
    (c) Citizenship
    N/A
    (d) Title of Class of Securities
    Common Stock
    (e) CUSIP Number
    G11196105
    Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
    (a) [ ] Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
    (b) [ ] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c) [ ] Insurance Company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d) [ ] Investment Company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e) [X] An investment adviser in accordance with Rule 240.13d-1(b)(1)(ii)(E);
    (f) [ ] An employee benefit plan or endowment fund in accordance with Rule 240.13d-1(b)(1)(ii)(F);
    (g) [ ] A parent holding company or control person in accordance with Rule 240.13d-1(b)(1)(ii)(G);
    (h) [ ] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i) [ ] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(J).
    Item 4. Ownership.
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
    (a) Amount Beneficially Owned:
    5,104,501 **
    (b) Percent of Class:
    7.8%
    (c) Number of shares as to which such person has:
    (i) sole power to vote or to direct the vote 5,102,981
    (ii) shared power to vote or to direct the vote 0
    (iii) sole power to dispose or to direct the disposition of 5,104,501
    (iv) shared power to dispose or to direct the disposition of 0
    **Capital International Investors ("CII") is a division of Capital Research and Management Company ("CRMC"), as well as its investment management subsidiaries and affiliates Capital Bank and Trust Company, Capital International, Inc., Capital International Limited, Capital International Sarl, Capital International K.K., and Capital Group Private Client Services, Inc. (together with CRMC, the "investment management entities"). CII's divisions of each of the investment management entities collectively provide investment management services under the name "Capital International Investors." CII is deemed to be the beneficial owner of 5,104,501 shares or 7.8% of the 65,501,261 shares believed to be outstanding.
    Item 5. Ownership of Five Percent or Less of Class.
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [ ]
    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
    The Growth Fund of America
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
    Not Applicable
    Item 8. Identification and Classification of Members of the Group.

    Not Applicable. This schedule is not being filed pursuant to Rule 13d-1(b)(1)(ii)(J) or Rule 13d-1(d).
    Item 9. Notice of Dissolution of Group.

    Not Applicable
    Item 10. Certification.

    By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Capital International Investors
    By: /s/ Walter R. Burkley
    Date: February 14, 2022
    Name: Walter R. Burkley
    Title: Senior Vice President and Senior Counsel, Fund Business Management Group, Capital Research and Management Company

    Get the next $BHVN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BHVN

    DatePrice TargetRatingAnalyst
    11/6/2025$9.00Outperform → Mkt Perform
    Bernstein
    11/5/2025$10.00Buy → Neutral
    BofA Securities
    9/17/2025$28.00Buy
    Citigroup
    9/3/2025$75.00Strong Buy
    Raymond James
    5/19/2025$21.00Outperform → Sector Perform
    RBC Capital Mkts
    2/11/2025$65.00Buy
    Deutsche Bank
    9/16/2024$57.00Buy
    Jefferies
    9/4/2024$55.00Outperform
    Bernstein
    More analyst ratings

    $BHVN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    VP, Chief Accounting Officer Clark George C. bought $144,770 worth of shares (17,000 units at $8.52) (SEC Form 4)

    4 - Biohaven Ltd. (0001935979) (Issuer)

    11/18/25 7:29:10 AM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Bailey Gregory bought $3,000,000 worth of shares (400,000 units at $7.50), increasing direct ownership by 25% to 2,020,071 units (SEC Form 4)

    4 - Biohaven Ltd. (0001935979) (Issuer)

    11/17/25 7:31:22 AM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Childs John W bought $24,999,998 worth of shares (3,333,333 units at $7.50) (SEC Form 4)

    4 - Biohaven Ltd. (0001935979) (Issuer)

    11/17/25 7:30:45 AM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHVN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    VP, Chief Accounting Officer Clark George C. bought $144,770 worth of shares (17,000 units at $8.52) (SEC Form 4)

    4 - Biohaven Ltd. (0001935979) (Issuer)

    11/18/25 7:29:10 AM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Bailey Gregory bought $3,000,000 worth of shares (400,000 units at $7.50), increasing direct ownership by 25% to 2,020,071 units (SEC Form 4)

    4 - Biohaven Ltd. (0001935979) (Issuer)

    11/17/25 7:31:22 AM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Childs John W bought $24,999,998 worth of shares (3,333,333 units at $7.50) (SEC Form 4)

    4 - Biohaven Ltd. (0001935979) (Issuer)

    11/17/25 7:30:45 AM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHVN
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Biohaven Ltd.

    SCHEDULE 13G - Biohaven Ltd. (0001935979) (Subject)

    11/14/25 10:28:52 AM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biohaven Ltd. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Biohaven Ltd. (0001935979) (Filer)

    11/13/25 4:27:36 PM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Biohaven Ltd.

    424B5 - Biohaven Ltd. (0001935979) (Filer)

    11/13/25 7:09:09 AM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHVN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $BHVN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Biohaven Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $200M

    NEW HAVEN, Conn., Nov. 13, 2025 /PRNewswire/ -- Biohaven Ltd. (NYSE:BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today announced the closing of its underwritten public offering of 26,833,334 of its common shares, which includes the full exercise of the underwriters' option to purchase 3,500,000 additional common shares, at a public offering prices of $7.50 per share. The offering was upsized to $175 million from the previously announced offering size of $150 million of common shares. The gross proceeds from the offering were approximately $200

    11/13/25 4:05:00 PM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biohaven Announces Pricing of $175 Million Public Offering of Common Shares

    NEW HAVEN, Conn., Nov. 12, 2025 /PRNewswire/ -- Biohaven Ltd. (NYSE:BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today announced the pricing of its underwritten public offering of 23,333,334 of its common shares at a price to the public of $7.50 per share.  In addition, Biohaven has granted the underwriters a 30-day option to purchase up to an additional 3,500,000 common shares at the public offering price, less underwriting discounts and commissions.  The gross proceeds from the offering are expected to be approximately $175 million before de

    11/12/25 7:15:00 AM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biohaven Announces Proposed Public Offering of Common Shares

    NEW HAVEN, Conn., Nov. 11, 2025 /PRNewswire/ -- Biohaven Ltd. (NYSE:BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today announced that it has commenced an underwritten public offering of $150 million of its common shares. All of the common shares to be sold in the offering will be offered by Biohaven. In addition, Biohaven expects to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of common shares at the public offering price, less underwriting discounts and commissions. The offering is subject to market and

    11/11/25 4:05:00 PM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biohaven downgraded by Bernstein with a new price target

    Bernstein downgraded Biohaven from Outperform to Mkt Perform and set a new price target of $9.00

    11/6/25 8:37:03 AM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biohaven downgraded by BofA Securities with a new price target

    BofA Securities downgraded Biohaven from Buy to Neutral and set a new price target of $10.00

    11/5/25 3:37:41 PM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citigroup initiated coverage on Biohaven with a new price target

    Citigroup initiated coverage of Biohaven with a rating of Buy and set a new price target of $28.00

    9/17/25 7:59:04 AM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHVN
    Financials

    Live finance-specific insights

    View All

    Biohaven Achieves Positive Topline Results in Pivotal Study of Troriluzole in Spinocerebellar Ataxia (SCA)

    Troriluzole 200 mg dosed orally, once daily, in patients with SCA met the study's primary endpoint on the change from baseline in the modified functional Scale for the Assessment and Rating of Ataxia (f-SARA) at 3 years in all study population genotypes.Troriluzole also showed statistically significant superiority after both 1 and 2 years of treatment.Troriluzole achieved statistically significant superiority on 9 consecutive, prespecified primary and secondary endpoints.SCA patients treated with troriluzole showed a 50-70% slowing of disease progression, representing 1.5-2.2 years delay in disease progression over the 3-year study period.Biohaven plans to submit a New Drug Application (NDA)

    9/23/24 7:30:00 AM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biohaven Announces Conference Call to Discuss Topline Pivotal Study Results in Spinocerebellar Ataxia

    Conference call and webcast to be held Monday, September 23, at 8:30am ET  NEW HAVEN, Conn., Sept. 20, 2024 /PRNewswire/ -- Biohaven Ltd. (NYSE:BHVN) (Biohaven), today announced that it will host a conference call to discuss topline data from Study BHV4157-206-RWE (NCT06529146), a study designed in discussion with the US Food and Drug Administration (FDA), to assess the effectiveness of troriluzole in Spinocerebellar Ataxia. Conference Call and Webcast DetailsBiohaven will hold a live conference call and webcast Monday, September 23, 2024, at 8:30 a.m. Eastern Time. The live e

    9/20/24 7:09:00 PM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biohaven Acquires Exclusive License for Oral, Brain-Penetrant, Dual TYK2/JAK1 Inhibitor for Immune-Mediated Brain Disorders

    Novel first-in-class, brain-penetrant, dual inhibitor of TYK2/JAK1 offers wide therapeutic index with TYK2 inhibition and high selectivity for JAK1 inhibition without the severely limiting adverse class effects of JAK2/JAK3 inhibitorsExclusive license covers global rights excluding China regionBiohaven anticipates initiating Phase 1 clinical development in 2023NEW HAVEN, Conn., March 22, 2023 /PRNewswire/ -- Biohaven Ltd. (NYSE:BHVN) today announced that it acquired global rights, excluding China regions, for the development of an oral, brain-penetrant, dual inhibitor of Tyrosine Kinase 2 (TYK2) and Janus Kinase 1 (JAK1) for the treatment of brain disorders. BHV-8000 (previously TLL-041) was

    3/22/23 7:30:00 AM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHVN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Biohaven Ltd.

    SC 13G/A - Biohaven Ltd. (0001935979) (Subject)

    11/14/24 3:06:46 PM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Biohaven Ltd.

    SC 13G/A - Biohaven Ltd. (0001935979) (Subject)

    11/12/24 1:20:24 PM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Biohaven Ltd.

    SC 13G/A - Biohaven Ltd. (0001935979) (Subject)

    11/4/24 11:16:33 AM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BHVN
    Leadership Updates

    Live Leadership Updates

    View All

    Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board

    WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, today announced the appointment of Michael Heffernan as Chairman of the Board of Directors ("Board"). Mr. Heffernan will succeed Dr. Garry Neil as Chairman of the Board. Dr. Neil will continue as a Board member and Chief Executive Officer (CEO) of the Company. "We are thrilled to welcome Michael to Avalo's Board of Directors during this pivotal time in our Company's growth," said Dr. Garry Neil, CEO of Avalo Therapeutics. "Michael's extensive experience in building and leading biopharmaceutical companie

    3/26/25 7:00:00 AM ET
    $AVTX
    $BHVN
    $COLL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Benitec Biopharma Announces Appointment of Kishen Mehta to its Board of Directors

    HAYWARD, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announces the appointment of Kishen Mehta to the board of directors (BOD) of the Company, effective June 26, 2024. Mr. Mehta's appointment follows the $40.0 million private investment in public equity (PIPE) financing announced on April 18th, led by long-term investor Suvretta Capital, where he serves as portfolio manager. "We are pleased to welcome Kishen to the board as we pl

    7/1/24 7:00:00 AM ET
    $BHVN
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biohaven Reports First Quarter 2023 Financial Results and Reports Recent Business Developments

    Acquired exclusive license for oral, brain-penetrant, dual TYK2/JAK1 inhibitor for immune-mediated brain disorders in March 2023 covering global rights (excluding China)Appointed Nick Kozauer, M.D. as SVP of Clinical Development and Regulatory Strategy following his tenure as Director of the Division of Neurology 2 in the Office of New Drugs of the U.S. Food and Drug AdministrationTaldefgrobep alfa granted Fast Track Designation in SMADriving strong and consistent progress across six robust drug development platforms in 2023:in Kv7 activation, targeting Phase 2/3 study start in focal epilepsy and bipolar disorder in the second half of 2023;Phase 1 study initiation planned with potentially fi

    5/12/23 4:30:00 PM ET
    $BHVN
    Biotechnology: Pharmaceutical Preparations
    Health Care